PTGER4 and pancreatic neoplasm: Thus, combined treatment with an sEH inhibitor and an EP4 antagonist prevents debris-stimulated tumor growth, prolongs survival in a metastatic pancreatic cancer model, and counterregulates the debris-stimulated cytokine storm in vivo.